Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Myelodysplastic/Myeloproliferative Neoplasms
NCT07549451Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2026
- Primary completion
- May 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imetelstat in myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Adverse Events at 1 year, Overall Response Rate at 1 year and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
imetelstat
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT07549451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549451.